Trial Profile
A prospective real life study evaluating correlation between baseline anti-cyclic citrullinated peptide 3 antibody titre and long-term drug survival of subcutaneous Abatacept in rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jul 2017
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- 08 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism